Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill & Intangibles (2016 - 2023)

Sangamo Therapeutics has reported Goodwill & Intangibles over the past 11 years, most recently at $51.6 million for Q1 2023.

  • Quarterly results put Goodwill & Intangibles at $51.6 million for Q1 2023, down 43.73% from a year ago — trailing twelve months through Mar 2023 was $51.6 million (down 43.73% YoY), and the annual figure for FY2022 was $88.3 million, down 5.54%.
  • Goodwill & Intangibles for Q1 2023 was $51.6 million at Sangamo Therapeutics, down from $88.3 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for SGMO hit a ceiling of $100.9 million in Q4 2020 and a floor of $51.6 million in Q1 2023.
  • Median Goodwill & Intangibles over the past 5 years was $92.5 million (2019), compared with a mean of $90.1 million.
  • Biggest five-year swings in Goodwill & Intangibles: skyrocketed 5810.85% in 2019 and later plummeted 43.73% in 2023.
  • Sangamo Therapeutics' Goodwill & Intangibles stood at $92.4 million in 2019, then grew by 9.19% to $100.9 million in 2020, then dropped by 7.4% to $93.5 million in 2021, then dropped by 5.54% to $88.3 million in 2022, then crashed by 41.6% to $51.6 million in 2023.
  • The last three reported values for Goodwill & Intangibles were $51.6 million (Q1 2023), $88.3 million (Q4 2022), and $81.0 million (Q3 2022) per Business Quant data.